Stuart Therapeutics Announces Positive Retinal Indication in vitro Results for PolyCol
April 22nd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD).
Stuart Therapeutics Receives Positive Response in Pre-IND Meeting with FDA for its Dry Eye Disease Therapeutic Candidate, ST-100
April 3rd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has successfully completed a pre-IND meeting regarding the development plan for ST-100, Stuart’s first drug candidate for Dry Eye Disease (DED). The meeting, held with the Food and Drug Administration’s Center
Stuart Therapeutics, Inc. Announces Relationship with Ora, Inc. for IND Preparation, Regulatory Advisory, and Clinical Trial Services for ST-100
STUART, FLORIDA February 25, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has retained the services of Ora®, Inc., the premier ophthalmology Contract Research Organization (“CRO”) globally, to provide various product development, IND preparation, regulatory advisory and clinical trial services for STUART’s first drug candidate, ST-100. ST-100 is